Monday December 18th 2017

Tumefactive Multiple Sclerosis in a Patient on Fingolimod (P2.226)

Conclusion:We discussed clinical presentation, radiological characteristics, and response to treatment in this patient with tumefactive MS on fingolimod. We speculate on possible causes and suggest more research into this rare phenomenon. We stress importance of pharmacovigilance in all novel therapies.Disclosure: Dr. Lee has nothing to disclose. Dr. Sawlani has nothing to disclose. Dr. Mazibrada has received personal compensation for activities with Biogen Idec, Novartis and Merck Serono as a speaker and advisory board member. (Source: Neurology)

View post¬†–¬†

Tumefactive Multiple Sclerosis in a Patient on Fingolimod (P2.226)

Leave a Comment

More from category

MS Activists Celebrate 2017 State Policy Impact
MS Activists Celebrate 2017 State Policy Impact

/About-the-Society/News/MS-Activists-Celebrate-2017-State-Policy-Impact [Read More]

MS Research Program Funding Authorized by President Trump
MS Research Program Funding Authorized by President Trump

/About-the-Society/News/MS-Research-Program-Funding-Authorized-by-Presiden [Read More]

Germany’s Merck to make new bid to enter U.S. MS pill market
Germany’s Merck to make new bid to enter U.S. MS pill market

FRANKFURT (Reuters) - Germany's Merck KGaA is reviving plans to bring an oral multiple sclerosis (MS) treatment to the [Read More]

Researchers develop new method for quickly detecting signs of multiple sclerosis
Researchers develop new method for quickly detecting signs of multiple sclerosis

A METHOD for quickly detecting signs of multiple sclerosis has been developed by a University of Huddersfield research [Read More]

Terror survivors have increased risk of frequent migraine, tension headaches
Terror survivors have increased risk of frequent migraine, tension headaches

Survivors of a terror attack have an increased risk of frequent migraine and tension headaches after the attack, [Read More]